Therapeutic Classification: abortifacients, antidiabetics
Pharmacologic Classification: antiprogestational agents
REMS
Mifeprex
Korlym
Absorption: Rapidly absorbed following oral administration (69% bioavailability); absorption enhanced with food.
Distribution: Unknown.
Protein Binding: 98%.
Half-Life: 18 hr.
Contraindicated in:
Use Cautiously in:
CV: hypertension (Korlym), peripheral edema (Korlym), QT interval prolongation (Korlym)
Derm: rash (Korlym)
Endo: hypothyroidism (Korlym), ↓HDL cholesterol (Korlym), adrenal insufficiency (Korlym)
F and E: hypokalemia (Korlym)
GI: abdominal pain (Mifeprex), anorexia (Korlym), constipation (Korlym), diarrhea, dry mouth (Korlym), nausea, vomiting
GU: uterine bleeding, uterine cramping (Mifeprex), pelvic pain (Mifeprex), ruptured ectopic pregnancy (Mifeprex)
MS: arthralgia (Korlym), myalgia (Korlym)
Neuro: anxiety (Korlym), dizziness, fatigue (Korlym), headache, fainting (Mifeprex), weakness (Mifeprex)
Resp: dyspnea (Korlym), Pneumocystis jirovecipneumonia
Misc: ANGIOEDEMA
Drug-drug:
Drug-Natural Products:
Mifeprex
Korlym
Renal Impairment
Hepatic Impairment
Lab Test Considerations:
Mifeprex is only available through a restricted program, mifepristone REMS program. Prescribers and pharmacies that dispense mifepristone must be certified by the program and patients must sign an agreement form.